Protein Kinase Inhibitors: all 15,278 studies that test it

Page 93 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
• Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) LymphomaStatus unknownNCT04431089Phase 2
• A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
• Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseStatus unknownNCT04424056Phase 3
• Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy SubjectsCompletedNCT04423601Phase 1
• A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid TumorsStatus unknownNCT04423380Phase 1
• The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced PneumoniaStatus unknownNCT04422678Phase 3
• A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With CancerCompletedNCT04419623Phase 1
• JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 1
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2
• Positioning Imatinib for Pulmonary Arterial HypertensionActive, not recruitingNCT04416750Phase 2
• Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorCompletedNCT04416516Phase 2
• The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaStatus unknownNCT04415385Phase 2
• X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
• A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal FunctionStatus unknownNCT04414852Phase 1
• Ruxolitinib in the Treatment of Covid-19Status unknownNCT04414098Phase 2
• AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingNCT04413201Phase 4
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
• Cabozantinib in High Grade Neuroendocrine NeoplasmsActive, not recruitingNCT04412629Phase 2
• A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant TumorStatus unknownNCT04412564Phase 2
• Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care TherapyWithdrawnNCT04412252Phase 2
• Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruitingNCT04411654Phase 1/2
• Afatinib in Advanced NRG1-Rearranged MalignanciesCompletedNCT04410653Phase 2
• A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsCompletedNCT04410094Phase 1
• A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male ParticipantsCompletedNCT04410081Phase 1
• SCMC Trial on KHE With KMP (V.2020)Status unknownNCT04409691Phase 1
• Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing HomesTerminatedNCT04409327Phase 2
• Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibTerminatedNCT04409223Phase 3
• A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 TabletsStatus unknownNCT04408079Phase 1
• Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerStatus unknownNCT04407988Phase 2
• Ursodeoxycholic Acid vs Metformin in Gestational Diabetes MellitusActive, not recruitingNCT04407650Phase 4
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).TerminatedNCT04404140Phase 1
• PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release FormulationCompletedNCT04403776Phase 1
• COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19CompletedNCT04403243Phase 2
• Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLTerminatedNCT04402723Phase 1
• A Bioequivalence Study of Famitinib Malate on Healthy Chinese VolunteersCompletedNCT04400123Phase 1
• Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic TrialStatus unknownNCT04399798Phase 2
• A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Phase 2
• A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Phase 2
• Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• Low Dose Ruxolitinib in Combination With MethylprednisoloneCompletedNCT04397367Phase 1/2
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingNCT04395677Phase 2
• A Bioavailability Study of SHR1459 on Healthy Chinese VolunteersCompletedNCT04395053Phase 1
• Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedNCT04394975Phase 3
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
• Abemaciclib and Letrozole to Treat Endometrial CancerActive, not recruitingNCT04393285Phase 2
• Baricitinib Compared to Standard Therapy in Patients With COVID-19Status unknownNCT04393051Phase 2
• LY3214996 Plus Abemaciclib in Recurrent Glioblastoma PatientsCompletedNCT04391595Early Phase 1
• Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC PatientsStatus unknownNCT04390984Phase 1
• Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.CompletedNCT04390776Phase 1
• mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Status unknownNCT04390464Phase 4
• TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaStatus unknownNCT04390061Phase 2
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04385654Phase 2
• A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04385550Phase 3
• Phase 1 Study of ATR-002CompletedNCT04385420Phase 1
• Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisActive, not recruitingNCT04384692Phase 2
• Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
• A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT04380012Phase 2
• A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknownNCT04379167Phase 2
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer PreventionActive, not recruitingNCT04375813Phase 2
• Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALLStatus unknownNCT04375683Phase 3
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
• Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19TerminatedNCT04373044Phase 2
• A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy SubjectsCompletedNCT04372407Phase 1
• A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy SubjectsCompletedNCT04372394Phase 1
• Sirolimus in COVID-19 Phase 1WithdrawnNCT04371640Phase 1
• A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownNCT04370405Phase 2
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
• Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast CancerCompletedNCT04367090Phase 1
• First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCStatus unknownNCT04363255Phase 2
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1
• Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
• Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib CreamCompletedNCT04361136Phase 1
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1
• Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedNCT04360915Phase 1
• Baricitinib Therapy in COVID-19CompletedNCT04358614Phase 2/3
• Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibStatus unknownNCT04358562Phase 2
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.CompletedNCT04355845Phase 1
• A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerStatus unknownNCT04355520Phase 1/2
• INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple MyelomaWithdrawnNCT04355039Phase 1
• Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell CarcinomaStatus unknownNCT04354961Phase 2
• Ruxolitinib to Combat COVID-19WithdrawnNCT04354714Phase 2
• Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Phase 2
• T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast CancerWithdrawnNCT04351230Phase 2
• First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19CompletedNCT04350736Phase 1
• Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT04350190Phase 2
• A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's PatientsCompletedNCT04350177Phase 1
• Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.CompletedNCT04348695Phase 2
• Safety and Efficacy of Ruxolitinib for COVID-19WithdrawnNCT04348071Phase 2/3
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorCompletedNCT04346381Phase 2
• A Phase II Study in Patients With Alopecia AreataCompletedNCT04346316Phase 2

← Protein Kinase Inhibitors overview